8-KOther Events

Edwards Lifesciences Corp 8-K Report (May 20, 2003)

Filed May 20, 2003For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) reported on May 20, 2003, the issuance of an additional $25 million in aggregate principal amount of its 3.875% convertible senior debentures due 2033. This issuance was to fulfill an over-allotment option, following a prior issuance of $125 million in similar debentures on May 9, 2003. The company has now successfully placed a total of $150 million of these convertible senior debentures. The debentures, along with the common stock issuable upon conversion, were offered through a private placement and have not been registered under the Securities Act of 1933. This means they were sold to sophisticated investors who were provided with a private offering memorandum. The filing clarifies that this report does not constitute an offer to sell or solicitations to buy these securities.

Key Highlights

  • 1Edwards Lifesciences issued an additional $25 million in 3.875% convertible senior debentures due 2033.
  • 2This issuance was a result of exercising an over-allotment option.
  • 3The total principal amount of these debentures issued now stands at $150 million ($125 million previously + $25 million additional).
  • 4The debentures were issued as part of a private offering.
  • 5The debentures and underlying common stock are not registered under the Securities Act of 1933.
  • 6The filing specifies the offering was made via a private offering memorandum.

Frequently Asked Questions

The additional $25 million issuance represents the full exercise of an over-allotment option by the underwriters, bringing the total principal amount of the 3.875% convertible senior debentures due 2033 sold to $150 million. This indicates strong demand from investors for this offering.

These debentures were likely offered privately to "accredited investors" or institutional investors who are deemed sophisticated enough to understand the risks involved. This allows companies to raise capital more quickly and with less regulatory burden than a public offering, as registration under the Securities Act of 1933 is not required.

Convertible debentures are debt instruments that can be converted into a predetermined number of shares of the issuing company's common stock. This provides investors with the potential for equity upside if the company's stock price increases, while still offering the security of a debt instrument.

The debentures mature in 2033 and carry a coupon rate of 3.875% per annum.